Susquehanna International Group’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$802K Buy
35,483
+8,189
+30% +$182K ﹤0.01% 8467
2025
Q4
$706K Buy
+27,294
New +$649K ﹤0.01% 8007
2025
Q3
Sell
-123,087
Closed -$3.02M 13520
2025
Q2
$2.94M Sell
123,087
-19,446
-14% -$490K ﹤0.01% 4997
2025
Q1
$3.54M Sell
142,533
-43,887
-24% -$1.05M ﹤0.01% 4324
2024
Q4
$3.51M Buy
186,420
+174,327
+1,442% +$3.06M ﹤0.01% 4168
2024
Q3
$182K Buy
12,093
+1,271
+12% +$21.7K ﹤0.01% 10556
2024
Q2
$310K Sell
10,822
-21,028
-66% -$598K ﹤0.01% 9371
2024
Q1
$931K Buy
31,850
+17,360
+120% +$533K ﹤0.01% 7086
2023
Q4
$489K Sell
14,490
-36,639
-72% -$1.07M ﹤0.01% 8718
2023
Q3
$1.57M Sell
51,129
-7,220
-12% -$260K ﹤0.01% 5633
2023
Q2
$2.34M Sell
58,349
-12,560
-18% -$519K ﹤0.01% 4841
2023
Q1
$2.89M Buy
70,909
+65,614
+1,239% +$2.61M ﹤0.01% 4402
2022
Q4
$204K Sell
5,295
-11,755
-69% -$572K ﹤0.01% 10071
2022
Q3
$907K Buy
+17,050
New +$948K ﹤0.01% 6890
2022
Q2
Sell
-3,108
Closed -$204K 13671
2022
Q1
$237K Sell
3,108
-4,754
-60% -$317K ﹤0.01% 10832
2021
Q4
$473K Buy
+7,862
New +$434K ﹤0.01% 9360
2021
Q3
Sell
-11,741
Closed -$677K 13339
2021
Q2
$712K Buy
11,741
+5,771
+97% +$365K ﹤0.01% 8700
2021
Q1
$418K Sell
5,970
-16,894
-74% -$1.21M ﹤0.01% 9882
2020
Q4
$1.37M Sell
22,864
-25,115
-52% -$1.47M ﹤0.01% 5958
2020
Q3
$2.88M Buy
47,979
+41,897
+689% +$2.43M ﹤0.01% 3934
2020
Q2
$319K Sell
6,082
-37,817
-86% -$1.58M ﹤0.01% 8251
2020
Q1
$1.47M Buy
+43,899
New +$1.82M ﹤0.01% 4534
2019
Q4
Sell
-25,626
Closed -$1.09M 10390
2019
Q3
$976K Sell
25,626
-4,270
-14% -$170K ﹤0.01% 5747
2019
Q2
$1.3M Buy
+29,896
New +$1.27M ﹤0.01% 5093
2019
Q1
Sell
-85,429
Closed -$3.33M 9573
2018
Q4
$3.67M Buy
85,429
+47,167
+123% +$2.2M ﹤0.01% 2648
2018
Q3
$1.88M Buy
38,262
+26,507
+225% +$1.15M ﹤0.01% 4110
2018
Q2
$377K Buy
+11,755
New +$406K ﹤0.01% 7389
2017
Q4
Sell
-102,025
Closed -$4.04M 9734
2017
Q3
$3.83M Buy
+102,025
New +$4.11M ﹤0.01% 2871
2017
Q1
Sell
-264,726
Closed -$11.4M 9684
2016
Q4
$8.55M Buy
264,726
+116,977
+79% +$3.9M ﹤0.01% 1710
2016
Q3
$5.06M Buy
147,749
+88,879
+151% +$3.48M ﹤0.01% 2219
2016
Q2
$1.99M Buy
58,870
+40,416
+219% +$1.99M ﹤0.01% 3585
2016
Q1
$978K Buy
18,454
+12,196
+195% +$713K ﹤0.01% 5130
2015
Q4
$481K Sell
6,258
-59,306
-90% -$3.36M ﹤0.01% 6841
2015
Q3
$2.69M Buy
65,564
+53,583
+447% +$3.28M ﹤0.01% 3699
2015
Q2
$847K Sell
11,981
-12,668
-51% -$998K ﹤0.01% 6566
2015
Q1
$2.19M Sell
24,649
-6,186
-20% -$628K ﹤0.01% 4156
2014
Q4
$2.73M Sell
30,835
-49,324
-62% -$4.67M ﹤0.01% 3887
2014
Q3
$7.77M Buy
80,159
+20,636
+35% +$2.01M ﹤0.01% 2419
2014
Q2
$5.47M Buy
59,523
+42,339
+246% +$3.22M ﹤0.01% 2927
2014
Q1
$1.2M Buy
17,184
+2,315
+16% +$157K ﹤0.01% 5186
2013
Q4
$855K Buy
+14,869
New +$782K ﹤0.01% 5768
2013
Q3
Sell
-12,456
Closed -$454K 8665
2013
Q2
$361K Buy
+12,456
New +$360K ﹤0.01% 6527

Other funds holding PCRX

Susquehanna International Group's PCRX Position: Q1 2026 in Review

Susquehanna International Group increased its Pacira BioSciences (PCRX) stake by 30% in Q1 2026, buying an estimated $182K and bringing the position to 35,483 shares worth $802K. The position accounts for ﹤0.01% of the portfolio, ranked #8467.

Susquehanna International Group first reported a position in PCRX in Q2 2013 and has held it in 42 quarters since. The position peaked at $8.55M in Q4 2016. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Susquehanna International Group held 35,483 shares of Pacira BioSciences worth $802K as of Q1 2026.
  • Susquehanna International Group bought 8,189 Pacira BioSciences shares in Q1 2026, an estimated $182K.
  • Pacira BioSciences made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8467 holding.
  • Susquehanna International Group first reported a position in Pacira BioSciences in Q2 2013 and has held it in 42 quarters since.
  • Susquehanna International Group's Pacira BioSciences position peaked at $8.55M in Q4 2016.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.